Babitt, Jodie L., Eisenga, Michele F., Haase, Volker H., Kshirsagar, Abhijit V., Levin, Adeera I., Locatelli, Francesco, Małyszko, Jolanta, Swinkels, Dorine W., Tarng, Der Cherng, Cheung, Michael, Jadoul, Michel y., Winkelmayer, Wolfgang C., Drüeke, Tilman Bernhard, Abu-Alfa, Ali K., Afsar, Bariş, Pai, Amy Barton, Besarab, Anatole, Moore, Geraldine Biddle, Casadevall, Nicole, Cases, Aleix, de Francisco, Ángel Luís Martín, Eckardt, Kai Uwe, Fishbane, Steven N., Fried, Linda F., Ganz, Tomas, Ginzburg, yelena Z., Gómez, Rafael, Goodnough, Lawrence Tim, Hamano, Takayuki, Hanudel, Mark R., Hao, Chuanming, Iseki, Kunitoshi, Ix, Joachim H., Johansen, Kirsten L., Ketteler, Markus, Kovesdy, Csaba P., Leaf, David E., Macdougall, Iain C., Massy, Ziad André, Mcmahon, Lawrence P., Minutolo, Roberto, Nakanishi, Takeshi, Nemeth, Elizabeta, Obrador, Gregorio T., Parfrey, Patrick S., Park, Hyeong-Cheon, Pecoits-Filho, Roberto, Robinson, Bruce M., Roger, Simon D., Shah, yatrik M., Spinowitz, Bruce S., Tanaka, Tetsuhiro, Tsukamoto, yusuke, Tungsanga, Kriang, Walther, Carl P., yee-Moon Wang, Angela yee Moon, Wolf, Myles, Babitt, Jodie, Eisenga, Michele, Haase, Volker, Kshirsagar, Abhijit, Levin, Adeera, Swinkels, Dorine, Tarng, Der-Cherng, Jadoul, Michel, Winkelmayer, Wolfgang, Dru ¨eke, Tilman, Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Hôpital Paul Brousse, National Institutes of Health, NIH: RO1-DK087727 Boehringer Ingelheim, BI Amgen Astellas Pharma US AstraZeneca Massachusetts General Hospital, MGH FibroGen AMAG Pharmaceuticals, This conference was sponsored by KDIGO and supported in part by unrestricted educational grants from Akebia Therapeutics, AMAG Pharmaceuticals , Amgen , Astellas, AstraZeneca , Boehringer Ingelheim, FibroGen , GlaxoSmithKline , Mitsubishi Tanabe Pharma Group, Pharmacosmos, Roche , Rockwell Medical, Torii Pharmaceutical, and Vifor Fresenius Medical Care Renal Pharma., JLB has declared receiving consulting fees from Disc Medicine and Incyte Corporation, equity ownership from Ferrumax Pharmaceuticals, research support from the National Institutes of Health (grant RO1-DK087727) and the Patricia and Scott Eston Massachusetts General Hospital Research Scholar Award, and patent royalties for intellectual property owned by Massachusetts General Hospital that is licensed to Ferrumax Pharmaceuticals on BMP and HJV targeted therapies for iron disorders. MFE has declared receiving consultant fees from Vifor Pharma, serving on the Advisory Board for Cablon Medical, and receiving speakers bureaus from Vifor Pharma. VHH has declared receiving consultant fees from Akebia Therapeutics, AstraZeneca, FibroGen, Incyte Corporation, and Rockwell Medical. AVK has declared receiving consultant fees from Rockwell Medical. AL has declared receiving consultant fees from AstraZeneca and research support from AstraZeneca. FL has declared receiving consultant fees from Amgen and AstraZeneca, and speakers bureaus from Amgen, AstraZeneca, and Roche. JM has declared receiving consultant fees from AstraZeneca and speakers bureaus from Bayer Healthcare. DWS has declared receiving consultant fees from Silence Therapeutics. MJ has declared receiving consultant fees from Astellas, AstraZeneca, Boehringer Ingelheim, Fresenius Medical Care Asia Pacific, Mundipharma, and Vifor Fresenius Medical Care, serving on speakers bureaus from Astellas, AstraZeneca, Mundipharma, and Vifor Fresenius Medical Care, and receiving research support from Amgen and future research support from AstraZeneca. WCW has declared receiving consultant fees from Akebia/Otsuka, AstraZeneca, Bayer Healthcare, Janssen, Merck, Reata, and Relypsa, future consultant fees from Boehringer Ingelheim, and research support from the National Institutes of Health. TBD has declared receiving consultancy fees from Astellas, GlaxoSmithKline, and KfH Stiftung, and future consultant fees from Astellas. All the other authors declared no competing interests., Babitt, J. L., Eisenga, M. F., Haase, V. H., Kshirsagar, A. V., Levin, A., Locatelli, F., Malyszko, J., Swinkels, D. W., Tarng, D. -C., Cheung, M., Jadoul, M., Winkelmayer, W. C., Drueke, T. B., Abu-Alfa, A. K., Afsar, B., Pai, A. B., Besarab, A., Moore, G. B., Casadevall, N., Cases, A., de Francisco, A., Eckardt, K. -U., Fishbane, S., Fried, L. F., Ganz, T., Ginzburg, Y. Z., Gomez, R., Goodnough, L. T., Hamano, T., Hanudel, M. R., Hao, C. -M., Iseki, K., Ix, J. H., Johansen, K. L., Ketteler, M., Kovesdy, C. P., Leaf, D. E., Macdougall, I. C., Massy, Z. A., Mcmahon, L. P., Minutolo, R., Nakanishi, T., Nemeth, E., Obrador, G. T., Parfrey, P. S., Park, H. -C., Pecoits-Filho, R., Robinson, B. M., Roger, S. D., Shah, Y. M., Spinowitz, B. S., Tanaka, T., Tsukamoto, Y., Tungsanga, K., Walther, C. P., Yee-Moon Wang, A., Wolf, M., UCL - SSS/IREC/NEFR - Pôle de Néphrologie, and UCL - (SLuc) Service de néphrologie